Keeps Biopharma Inc. (KOSDAQ:256940)
South Korea · Delayed Price · Currency is KRW 5,650.00
+300.00 (5.61%)
At close: Aug 24, 2026
Keeps Biopharma Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 107,418 | 208,813 | 97,681 | 119,991 | 127,866 | 235,610 | |
Market Cap Growth | -53.19% | 113.77% | -18.59% | -6.16% | -45.73% | -23.77% |
Enterprise Value | 189,729 | 254,805 | 122,355 | 160,512 | 124,281 | 215,414 |
Last Close Price | 5350.00 | 10400.00 | 5210.00 | 6400.00 | 6820.00 | 13100.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 87.73 | 30.53 | - | - |
Forward PE | - | 16.78 | 3.21 | 3.21 | 3.21 | 3.21 |
PS Ratio | 0.57 | 1.23 | 0.77 | 1.30 | 8.75 | 55.30 |
PB Ratio | 1.26 | 2.56 | 1.54 | 2.05 | 2.45 | 3.87 |
P/TBV Ratio | 7.49 | 19.72 | 10.43 | 4.50 | 2.45 | 3.92 |
P/OCF Ratio | - | - | 20.31 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.00 | 1.50 | 0.96 | 1.74 | 8.50 | 50.56 |
EV/EBITDA Ratio | 50.42 | 42.03 | 13.89 | 35.65 | - | - |
EV/EBIT Ratio | - | 161.82 | 19.65 | 52.45 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.11 | 1.14 | 0.88 | 0.83 | 0.55 | 0.45 |
Debt / EBITDA Ratio | 17.13 | 15.27 | 6.33 | 10.73 | - | - |
Net Debt / Equity Ratio | 0.75 | 0.81 | 0.52 | 0.64 | 0.07 | -0.22 |
Net Debt / EBITDA Ratio | 11.52 | 10.89 | 3.72 | 8.31 | -0.46 | 1.16 |
Net Debt / FCF Ratio | -1.49 | -1.41 | -18.32 | -35.68 | -3.76 | 1.57 |
Asset Turnover | 0.89 | 0.85 | 0.90 | 0.91 | 0.16 | 0.05 |
Inventory Turnover | 5.74 | 5.10 | 8.57 | 22.90 | 7.05 | 4.01 |
Quick Ratio | 0.68 | 0.54 | 0.46 | 0.40 | 0.99 | 1.59 |
Current Ratio | 1.26 | 1.15 | 0.82 | 0.84 | 1.35 | 2.10 |
Return on Equity (ROE) | -4.19% | -14.33% | 2.64% | 6.25% | -21.28% | -29.03% |
Return on Assets (ROA) | 0.24% | 0.49% | 2.74% | 1.89% | -6.23% | -9.03% |
Return on Invested Capital (ROIC) | 0.55% | 1.29% | 3.10% | 2.60% | -17.23% | -28.11% |
Return on Capital Employed (ROCE) | 0.50% | 1.10% | 7.70% | 5.00% | -16.70% | -19.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -2.22% | -4.69% | 1.14% | 3.28% | -8.90% | -6.50% |
FCF Yield | -39.74% | -22.44% | -1.83% | -0.87% | -0.75% | -3.60% |
Buyback Yield / Dilution | -5.38% | -3.95% | -0.31% | -0.40% | -8.22% | -18.22% |